Just something to think about for those investors sitting around the sidelines here.
As some of you are aware that this company's CEO, Russ Mitchell has successfully brought pain relief products to retail exposure in the past with his first product being Cold-eze. Lipigesic M was also brought to market by Russ a number of years ago, however was unsuccessful with sales due to pricing, consumer awareness, and a recall on the packaging.
Prior to the release of Lipigesic M to the retail public, this company was trading in the $.05 - $.10 range with a market cap under $1 million. The pps did not stay where it was for long once, things started to roll out with Lipigesic M. quickly rising to over $1.50 and a market cap of approx. $20 million. Coincidently, a similar amount of debt had been accumulated in that time for product research, clinical trials, manufacturing, and distribution.
Although, Lipigesic M in the end was not a success for reasons listed above, it still is a success when it comes to efficacy and consumer satisfaction for control of migraine headaches for a large majority that use it.
So now along comes a new product of PMBS, MigraPure, a better formulation, similar in its effectiveness. Even at a billion shares outstanding, market cap today is between $100,000 and $200,000.
Please do your due diligence, follow the progress of this new product with the likelihood of other new products to follow, and realize that if history does indeed repeat itself, that this company is in an ideal position should MigraPure prove to be a hit.
AI
